Comparing the effects of live versus recorded relaxation on mood, coping, and quality of life on patients with cancer

A pragmatic, randomised controlled trial of the effects of live relaxation on mood, coping, and quality of life on patients with cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN72222248

Enrollment

156

Registered

2010-05-07

Start date

2008-01-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Various cancers

Interventions

All interventions will be carried out in the Oncology Health Centres at Castle Hill and Princess Royal Hospitals, Kingston upon Hull (House of Commons, 2004

Walker et al., 2003 a and b). Patients will be randomised to one of two interventions: 1. Patients randomised to RECREL will be taught progressive muscular relaxation and cue-controlled relaxation (H

Ratcliffe et al., 1995, Walker et al., 1999a). Each therapist will record these scripts in his/her own voice. Patients will be asked to practice once daily at home for 8 weeks (daily diary records to

Walker et al., 2003 a and b). This includes access to the Clinical and Research Nurse Specialists (Behavioural Oncology) and, if indicated clinically, the clinical ps

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. At least 18 years of age 2. Histologically confirmed colorectal cancer, gynaecological cancer (ovarian, endometrial, cervical) lung, or prostate cancer. 3. Accessing the Oncology Health Service for the first time

Exclusion criteria

Exclusion criteria: 1. WHO performance status 2, 3 and 4; 2. Clinically significant cognitive impairment or dementia 3. Inability to complete Quality of Life questionnaires 4. Inability or unwillingness to give informed consent 5. History of functional psychosis.

Design outcomes

Primary

Measure	Time frame
Relaxation scale score on the Mood Rating Scale (MRS), (Anderson et al., 2000; Johnson et al., 1996; Walker et al., 1997; Walker et al., 1999; Wesnes et al., 1997b), measured at 8 weeks	—

Secondary

Measure	Time frame
1. Functional Assessment of Cancer Therapy: General version (FACT-G) (Cella et al., 1993) 2. Hospital Anxiety and Depression Scores (HADS) (Hermann, 1997; Walker et al., 1999; Zigmond & Snaith, 1983) 3. Mood Rating Scale (MRS) (remaining scales) (Anderson et al., 2000; Johnson et al., 1996; Walker et al., 1997; Walker et al., 1999; Wesnes et al., 1997) 4. Brief Profile of Mood States (Cella et al, 1987) 5. EuroQol (EQ-5D) (Brooks, 1996; EuroQoL Group, 1990) 6. Health Service Use (HSU) 7. Social Support Questionnaire (SSQ) 8. Patient Satisfaction Questionnaire (PSQ) (Walker et al., 1999) All secondary outcomes will be measured at 4 and 12 weeks.	—

Measure

Time frame

1. Functional Assessment of Cancer Therapy: General version (FACT-G) (Cella et al., 1993) 2. Hospital Anxiety and Depression Scores (HADS) (Hermann, 1997; Walker et al., 1999; Zigmond & Snaith, 1983) 3. Mood Rating Scale (MRS) (remaining scales) (Anderson et al., 2000; Johnson et al., 1996; Walker et al., 1997; Walker et al., 1999; Wesnes et al., 1997) 4. Brief Profile of Mood States (Cella et al, 1987) 5. EuroQol (EQ-5D) (Brooks, 1996; EuroQoL Group, 1990) 6. Health Service Use (HSU) 7. Social Support Questionnaire (SSQ) 8. Patient Satisfaction Questionnaire (PSQ) (Walker et al., 1999) All secondary outcomes will be measured at 4 and 12 weeks.

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026